Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.

Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G.

Sci Rep. 2017 Dec 22;7(1):18086. doi: 10.1038/s41598-017-17329-7.

2.

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Herter S, Herting F, Muth G, van Puijenbroek E, Schlothauer T, Ferrara C, Brady K, Lang S, Bacac M, Mössner E, Umana P, Klein C.

Haematologica. 2018 Feb;103(2):e78-e81. doi: 10.3324/haematol.2017.178996. Epub 2017 Oct 27. No abstract available.

3.

Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.

Herting F, Friess T, Umaña P, Middleton S, Klein C.

Leuk Lymphoma. 2018 Jun;59(6):1482-1485. doi: 10.1080/10428194.2017.1376740. Epub 2017 Sep 15. No abstract available.

PMID:
28914567
4.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

5.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

6.

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.

Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, Weller M.

Neuro Oncol. 2016 Sep;18(9):1242-52. doi: 10.1093/neuonc/now043. Epub 2016 Mar 23.

7.

Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).

Herting F, Herter S, Friess T, Muth G, Bacac M, Sulcova J, Umana P, Dangl M, Klein C.

Eur J Haematol. 2016 Nov;97(5):461-470. doi: 10.1111/ejh.12756. Epub 2016 Apr 18.

PMID:
26993060
8.

An integrated approach to quantitative modelling in angiogenesis research.

Connor AJ, Nowak RP, Lorenzon E, Thomas M, Herting F, Hoert S, Quaiser T, Shochat E, Pitt-Francis J, Cooper J, Maini PK, Byrne HM.

J R Soc Interface. 2015 Sep 6;12(110):0546. doi: 10.1098/rsif.2015.0546.

9.

Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab.

Bittner B, Richter WF, Hourcade-Potelleret F, Herting F, Schmidt J.

Drug Res (Stuttg). 2014 Nov;64(11):569-75. doi: 10.1055/s-0033-1363993. Epub 2014 Jan 22. Review.

PMID:
24452524
10.

Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.

Wartha K, Herting F, Hasmann M.

Pharmacol Ther. 2014 Jun;142(3):351-61. doi: 10.1016/j.pharmthera.2014.01.001. Epub 2014 Jan 8. Review.

PMID:
24412280
11.

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.

Herting F, Friess T, Bader S, Muth G, Hölzlwimmer G, Rieder N, Umana P, Klein C.

Leuk Lymphoma. 2014 Sep;55(9):2151-5160. doi: 10.3109/10428194.2013.856008. Epub 2014 Feb 4.

12.

Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.

Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M.

Clin Cancer Res. 2013 Dec 15;19(24):6730-40. doi: 10.1158/1078-0432.CCR-13-0081. Epub 2013 Oct 4.

13.

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.

14.

Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.

Oude Munnink TH, Tamas KR, Lub-de Hooge MN, Vedelaar SR, Timmer-Bosscha H, Walenkamp AM, Weidner KM, Herting F, Tessier J, de Vries EG.

J Nucl Med. 2013 Jun;54(6):929-35. doi: 10.2967/jnumed.112.112086. Epub 2013 Apr 26.

15.

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

16.

Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen.

Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, Schmidt J.

Arzneimittelforschung. 2012 Sep;62(9):401-9. doi: 10.1055/s-0032-1321831. Epub 2012 Aug 23. Review. Erratum in: Arzneimittelforschung. 2013 Nov;63(11):602.

PMID:
22918857
17.

Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.

Weigand S, Herting F, Maisel D, Nopora A, Voss E, Schaab C, Klammer M, Tebbe A.

Cancer Res. 2012 Sep 1;72(17):4329-39. doi: 10.1158/0008-5472.CAN-12-0136. Epub 2012 Jul 9.

18.

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.

Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C, Dumontet C.

Mol Cancer Ther. 2011 Jan;10(1):178-85. doi: 10.1158/1535-7163.MCT-10-0385.

19.

Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs.

Mikaelian I, Buness A, de Vera-Mudry MC, Kanwal C, Coluccio D, Rasmussen E, Char HW, Carvajal V, Hilton H, Funk J, Hoflack JC, Fielden M, Herting F, Dunn M, Suter-Dick L.

Toxicol Sci. 2010 Sep;117(1):144-51. doi: 10.1093/toxsci/kfq189. Epub 2010 Jul 12.

PMID:
20624997

Supplemental Content

Loading ...
Support Center